Should we accept a higher cost per health improvement for orphan drugs? A review and analysis of egalitarian arguments
In recent years, the issue of accepting a higher cost per health improvement for orphan drugs has been the subject of discussion in health care policy agencies and the academic literature. This article aims to provide an analysis of broadly egalitarian arguments for and against accepting higher cost...
| Authors: | ; ; ; |
|---|---|
| Format: | Electronic Article |
| Language: | English |
| Check availability: | HBZ Gateway |
| Journals Online & Print: | Drawer...
|
| Fernleihe: | Fernleihe für die Fachinformationsdienste |
| Published: |
Wiley-Blackwell
[2021]
|
| In: |
Bioethics
Year: 2021, Volume: 35, Issue: 4, Pages: 307-314 |
| IxTheo Classification: | NCC Social ethics NCH Medical ethics |
| Further subjects: | B
Opportunity Cost
B cost-effectiveness B Health economics B orphan drugs B Equality B drug prices B priority setting |
| Online Access: |
Presumably Free Access Volltext (lizenzpflichtig) Volltext (lizenzpflichtig) |